Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trialAthol U. Wells, Daniel F. Dilling, Manuel Quaresma et al.|The Lancet Respiratory Medicine|2020Cited by 558
Extracellular Mitochondrial DNA Is Generated by Fibroblasts and Predicts Death in Idiopathic Pulmonary FibrosisChangwan Ryu, Glenda Trujillo, Huanxing Sun et al.|American Journal of Respiratory and Critical Care Medicine|2017Cited by 172
2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic DiseasesSindhu R. Johnson, Jake G. Natalini, Elana J. Bernstein et al.|Arthritis & Rheumatology|2024Cited by 162
Validation of the prognostic value of <scp>MMP</scp>‐7 in idiopathic pulmonary fibrosisArgyris Tzouvelekis, Naftali Kaminski, Jose D. Herazo‐Maya et al.|Respirology|2016Cited by 134
2023 American College of Rheumatology (<scp>ACR</scp>)/American College of Chest Physicians (<scp>CHEST</scp>) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic DiseasesSindhu R. Johnson, Jake G. Natalini, Elana J. Bernstein et al.|Arthritis & Rheumatology|2024Cited by 122